Phase 3 Blinatumomab in Philadelphia negative B-precursor ALL

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

• IRAS ID

  134228

• Contact name

  Adele Fielding

• Contact email

  a.fielding@ucl.ac.uk

• Sponsor organisation

  Amgen Inc

• Eudract number

  2013-000536-10

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  14/LO/0036

• Date of REC Opinion

  12 Feb 2014

• REC opinion

  Further Information Favourable Opinion